Common use of Collaboration Product Development Clause in Contracts

Collaboration Product Development. Subject to Article 9 if the Parties Co-Promote, Warner shall be responsible for all costs of conducting Development of Collaboration Product(s) in the Territory, including, without limitation, expenses incurred in conducting clinical trials for Collaboration Products for which it retains commercialization rights thereto. In addition, Warner shall be responsible, at its sole expense, for all commercialization of such Collaboration Product(s) in the Territory so long as Warner retains rights thereto under this Agreement. During the term of this Agreement, Warner shall keep GenVec fully informed of its activities subject to this Agreement, including without limitation, the achievement of the milestones set forth in Sections 6.4 and 8.2.2 and the commercialization of the Collaboration Product(s). On or before January 31 of each year, at GenVec's request, Warner shall provide GenVec with a written report summarizing such events and activities and detailing those which have not been previously reported. When a registration package requesting approval for commercial sale of any Collaboration Product is first filed in any country within the Territory, and when approval is received therefor, Warner will immediately notify GenVec in writing.

Collaboration Product Development. Subject to Article 9 if the --------------------------------- Parties Co-Promote, Warner shall be responsible for all costs of conducting Development of Collaboration Product(s) in the Territory, including, without limitation, expenses incurred in conducting clinical trials for Collaboration Products for which it retains commercialization rights thereto. In addition, Warner shall be responsible, at its sole expense, for all commercialization of such Collaboration Product(s) in the Territory so long as Warner retains rights thereto under this Agreement. During the term of this Agreement, Warner shall keep GenVec fully informed of its activities subject to this Agreement, including without limitation, the achievement of the milestones set forth in Sections 6.4 and 8.2.2 and the commercialization of the Collaboration Product(s). On or before January 31 of each year, at GenVec's request, Warner shall provide GenVec with a written report summarizing such events and activities and detailing those which have not been previously reported. When a registration package requesting approval for commercial sale of any Collaboration Product is first filed in any country within the Territory, and when approval is received therefor, Warner will immediately notify GenVec in writing.